Micrornas in neurodegenerative disorders
AssigneesThe Brigham and Women S Hospital, Inc., The General Hospital Corporation
InventorsHoward Weiner, Oleg Butovsky, Merit Cudkowicz, James Berry
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA has-miR-155.
Claims11
A method of treating a subject having Alzheimer's Disease (AD), the method comprising identifying a subject who has AD and administering to the subject having AD at least one inhibitory nucleic acid comprising a sequence that is complementary to mature microRNA hsa-miR-155 having the sequence of SEQ ID NO:58, wherein the inhibitory nucleic acid reduces a level or activity of hsa-miR-155 in monocytes of the subject.
Dependencies are inferred from the claim text.